

WIKINGO Project Systematic Analysis

Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

Contents

List of Tables

1	Participant characteristics	3
2	According to Local Recurrence	4
3	According to Metastasis	6
4	According to Exitus	8
5	Incidence by outcome [95% CI]	13

List of Figures

1	Local Recurrence	5
2	Metastasis	7
3	Exitus	9
4	Local Recurrence, according to Type of Resection:	10
5	Metastasis, according to Type of Resection:	11
6	Survival, according to Type of Resection:	12

Table 1: Participant characteristics

	[ALL] N=250	N
Age	68.3 (11.7)	250
Sex: Men	159 (63.6%)	250
Tumor level:		250
0-6cm	92 (36.8%)	
7-12cm	155 (62.0%)	
13-15cm	3 (1.20%)	
Tumor stage:		250
0	29 (11.6%)	
I	74 (29.6%)	
II	70 (28.0%)	
III	77 (30.8%)	
Neoadjuvant treatment	187 (74.8%)	250
Type of resection:		250
Abdominoperineal resection	43 (17.2%)	
Anterior resection	200 (80.0%)	
Hartmann	7 (2.80%)	
Perforation	2 (0.80%)	250
Invasion circumferential margin	3 (1.20%)	250
Mesorecto quality:		250
Satisfactory	189 (75.6%)	
Partial	47 (18.8%)	
No-satisfactory	14 (5.60%)	
Recidive	8 (3.20%)	250
Months to recidive	20.0 [9.25;35.8]	250
Metastasis	23 (9.20%)	250
Months to Metastasis	19.0 [6.50;33.0]	250
Exitus	33 (13.2%)	250
Months to exitus	20.0 [11.0;37.5]	250


Table 2: According to Local Recurrence

	No event n= 242	Event n= 8	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.84 (1.16)	6.62 (1.39)	0.90 [0.50;1.60]	0.709	0.70 [0.32; 1.53]	0.378
Sex: Men	155 (64.0%)	4 (50.0%)	0.57 [0.14;2.30]	0.432	0.56 [0.11; 2.86]	0.489
Tumor level:						
0-6cm	90 (37.2%)	2 (25.0%)	810637 [0.00;.]	0.999	100.60 [7.37;1373.00]	<0.001
7-12cm	149 (61.6%)	6 (75.0%)	1554468 [0.00;.]	0.999	NA [NA; NA]	
Tumor stage:						
0	29 (12.0%)	0 (0.00%)	1.01 [0.00;.]	1.000	0.49 [0.00; Inf]	1
II	66 (27.3%)	4 (50.0%)	464867572 [0.00;.]	0.998	602909104.82 [0.00; Inf]	0.998
III	73 (30.2%)	4 (50.0%)	484045382 [0.00;.]	0.998	657146175.12 [0.00; Inf]	0.998
Neoadjuvant treatment	182 (75.2%)	5 (62.5%)	0.53 [0.13;2.23]	0.388	0.41 [0.05; 3.77]	0.432
Type of resection:						
Abdominoperineal resection	42 (17.4%)	1 (12.5%)	0.67 [0.08;5.61]	0.714	0.50 [0.01; 18.83]	0.711
Hartmann	6 (2.48%)	1 (12.5%)	5.97 [0.70;50.8]	0.102	14.75 [0.62; 348.81]	0.095
Perforation	2 (0.83%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	1
Invasion circumferential margin	3 (1.24%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	1
Mesorecto quality:						
Partial	45 (18.6%)	2 (25.0%)	1.95 [0.36;10.7]	0.441	0.91 [0.09; 9.21]	0.934
No-satisfactory	12 (4.96%)	2 (25.0%)	4.78 [0.87;26.2]	0.071	11.39 [0.94; 137.82]	0.056

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	250	176	99	60	45	19


Table 3: According to Metastasis

	No event n= 227	Event n= 23	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.87 (1.14)	6.45 (1.36)	0.79 [0.57;1.10]	0.163	0.78 [0.53; 1.14]	0.197	250
Sex: Men	145 (63.9%)	14 (60.9%)	0.86 [0.37;1.98]	0.719	1.34 [0.52; 3.43]	0.541	250
Tumor level:							250
0-6cm	83 (36.6%)	9 (39.1%)	1211221 [0.00;.]	0.998	3479881.73 [0.00; Inf]	0.999	
7-12cm	141 (62.1%)	14 (60.9%)	1216783 [0.00;.]	0.998	4246515.82 [0.00; Inf]	0.999	
Tumor stage:							250
0	28 (12.3%)	1 (4.35%)	0.80 [0.09;7.17]	0.841	0.81 [0.09; 7.57]	0.853	
II	64 (28.2%)	6 (26.1%)	1.79 [0.51;6.36]	0.366	2.01 [0.54; 7.43]	0.294	
III	65 (28.6%)	12 (52.2%)	3.83 [1.23;11.9]	0.020	4.00 [1.25;12.82]	0.02	
Neoadjuvant treatment	170 (74.9%)	17 (73.9%)	0.92 [0.36;2.34]	0.861	0.83 [0.27; 2.56]	0.745	250
Type of resection:							250
Abdominoperineal resection	38 (16.7%)	5 (21.7%)	1.27 [0.47;3.44]	0.641	1.56 [0.35; 6.87]	0.557	
Hartmann	6 (2.64%)	1 (4.35%)	1.75 [0.23;13.2]	0.585	2.03 [0.22;19.11]	0.536	
Perforation	2 (0.88%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998	250
Invasion circumferential margin	3 (1.32%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998	250
Mesorecto quality:							250
Partial	40 (17.6%)	7 (30.4%)	1.93 [0.78;4.80]	0.155	1.74 [0.63; 4.81]	0.29	
No-satisfactory	12 (5.29%)	2 (8.70%)	1.43 [0.32;6.30]	0.638	1.60 [0.30; 8.58]	0.582	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	250	173	95	57	43	19


Table 4: According to Exitus

	No event n= 217	Event n= 33	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.73 (1.17)	7.50 (0.95)	1.93 [1.33;2.81]	0.001	2.49 [1.55; 3.98]	<0.001	250
Sex: Men	135 (62.2%)	24 (72.7%)	1.53 [0.71;3.30]	0.275	1.45 [0.64; 3.31]	0.376	250
Tumor level:							250
0-6cm	83 (38.2%)	9 (27.3%)	2416530 [0.00;.]	0.998	33606503.23 [0.00; Inf]	0.999	
7-12cm	131 (60.4%)	24 (72.7%)	4016239 [0.00;.]	0.998	37670330.71 [0.00; Inf]	0.999	
Tumor stage:							250
0	29 (13.4%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.997	
II	57 (26.3%)	13 (39.4%)	2.13 [0.85;5.33]	0.108	1.26 [0.49; 3.27]	0.636	
III	64 (29.5%)	13 (39.4%)	2.12 [0.84;5.31]	0.110	2.30 [0.88; 5.99]	0.088	
Neoadjuvant treatment	164 (75.6%)	23 (69.7%)	0.77 [0.37;1.62]	0.490	1.93 [0.80; 4.69]	0.144	250
Type of resection:							250
Abdominoperineal resection	39 (18.0%)	4 (12.1%)	0.59 [0.21;1.67]	0.316	0.58 [0.13; 2.56]	0.473	
Hartmann	7 (3.23%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.998	
Perforation	2 (0.92%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999	250
Invasion circumferential margin	3 (1.38%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999	250
Mesorrecto quality:							250
Partial	39 (18.0%)	8 (24.2%)	1.40 [0.62;3.15]	0.414	1.73 [0.73; 4.06]	0.21	
No-satisfactory	11 (5.07%)	3 (9.09%)	1.36 [0.41;4.56]	0.616	9.98 [2.02;49.36]	0.005	

Reference categories:


- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus




Months	0	12	24	36	48	60
N:	250	178	101	63	47	19

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	43	30	21	13	11	2
Ant	200	142	80	49	36	17
H	7	5	2	1	0	0

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	43	30	19	11	9	2
Ant	200	141	77	47	35	17
H	7	5	3	1	0	0

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	43	31	21	13	11	2
Ant	200	144	81	50	37	17
H	7	5	3	2	1	0

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	1.59 [3.36; 0]	3.12 [5.55; 0.62]	7.17 [10.63; 3.58]
24	3.84 [6.86; 0.72]	10.54 [15.25; 5.58]	13.42 [18.27; 8.27]
36	5.36 [9.5; 1.03]	13.85 [19.59; 7.71]	14.54 [19.77; 8.97]
48	5.36 [9.5; 1.03]	16.88 [23.64; 9.52]	23.12 [30.84; 14.55]
60	7.73 [13.69; 1.35]	19.06 [26.74; 10.58]	25.32 [33.77; 15.8]